A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib

PURPOSE: The Hedgehog pathway inhibitor vismodegib exhibits pH-dependent solubility, and in vitro studies have shown that vismodegib is a substrate of P-glycoprotein (P-gp) and is metabolized by cytochrome P450 (CYP) 2C9 and 3A4. The objective of this four-arm parallel study in healthy subjects was...

Descripción completa

Detalles Bibliográficos
Autores principales: Malhi, Vikram, Colburn, Dawn, Williams, Sarah J., Hop, Cornelis E. C. A., Dresser, Mark J., Chandra, Priya, Graham, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921109/
https://www.ncbi.nlm.nih.gov/pubmed/27154174
http://dx.doi.org/10.1007/s00280-016-3020-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921109/
https://www.ncbi.nlm.nih.gov/pubmed/27154174
http://dx.doi.org/10.1007/s00280-016-3020-z

Ejemplares similares